Bharat Biotech Collaborates with Alopexx for Anti-Microbial Vaccine Development
Bharat Biotech is taking significant steps in the biotech arena by partnering with Alopexx, Inc. to co-develop and commercialize AV0328, an innovative broad-spectrum anti-microbial vaccine. This vaccine targets poly N-acetyl glucosamine (PNAG) and aims to address rising concerns around antimicrobial resistance, particularly in low-income countries.
The Collaboration Details
As part of this collaboration, Bharat Biotech and Alopexx will share responsibilities in the development of AV0328. This partnership allows both companies to leverage their strengths while focusing on the urgent health needs of underserved regions.
Financial Aspects
Alopexx will receive a one-time upfront payment along with milestone payments and royalties based on the future sales of AV0328 across licensed territories.
Statements from Leaders
Krishna Ella, Executive Chairman of Bharat Biotech, expressed pride in teaming up with Alopexx to deliver AV0328 where it is critically needed. He emphasized the importance of combatting antimicrobial resistance through effective vaccination strategies. Similarly, Daniel Vlock, CEO of Alopexx, highlighted that this partnership is pivotal in addressing the substantial need for effective antimicrobial solutions in economically challenged regions.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.